Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU) and BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) has agreed to a $490 million deal for a program targeting a rare bone disease. The acquisition is aimed at expanding the company's portfolio in the rare disease space, according to the company.

Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.

BioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.

BioMarin (BMRN) agreed to acquire Alesta Therapeutics for $275M upfront, with up to $215M in milestones. The deal expands BioMarin's rare disease pipeline, adding ALE1, a potential oral treatment for hypophosphatasia. BioMarin shares rose 4.7% premarket. The acquisition will be funded with existing cash and is expected to close this quarter.

BioMarin Pharmaceutical (BMRN) acquired Alesta Therapeutics for $275M upfront, gaining rights to ALE1, an oral treatment for hypophosphatasia (HPP). ALE1 is in early trials, with BioMarin potentially paying $215M more if milestones are met. The deal aligns with BioMarin's focus on rare skeletal diseases and follows its $4.8B acquisition of Amicus Therapeutics.

BioMarin Pharmaceutical (BMRN) rose 3.5% after acquiring Alesta Therapeutics for $275M upfront, with up to $215M in milestones. Analysts reacted positively, with Barclays and Piper Sandler raising price targets. The stock closed at $69.33, near its 52-week high.